Skip to main content

Table 5 Evaluation of factors affecting time to treatmenta

From: Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study

Effect (numerator) Odds ratio 95% CI P value
Univariate analysisb
 Attack frequency (≥ 10 attacks/year) 2.48 < 0.001
 BMI (≥ 25 kg/m2) 1.77 0.012
 Type of administration (HCP) 0.55 0.067
 Country    < 0.0001c
Multivariate analysisd
 Attack frequency (≥ 10 attacks/year)e 2.89 1.36–6.14 0.0056
 BMI (≥ 25 kg/m2)e 1.71 1.06–2.79 0.0295
  1. BMI body mass index; CI confidence interval; HCP health care provider
  2. aModel of probability that time to treatment < 1 h
  3. bOnly effects with P < 0.2 are shown. Complete results are presented in Additional file 1: Table S5
  4. cOverall effect of country on time to treatment
  5. dOnly significant effects are shown
  6. eResults were similar when data from the two reinjection outliers were excluded (Additional file 1: Table S6)